Risk of mortality in patients with cancer who experience febrile neutropenia

Gary H. Lyman, Shannon L. Michels, Matthew W. Reynolds, +3

Cancer

Determinants of imminent fracture risk in postmenopausal women with osteoporosis

Rich Barron, Gerry Oster, Andreas Grauer, +2

Osteoporosis International

Reliability and Validity of the Incontinence Quality of Life Questionnaire in Patients With Neurogenic Urinary Incontinence

Brigitte Schurch, P. Denys, Chris M Kozma, +3

Archives of Physical Medicine and Rehabilitation

ReliabilityQuality Of LifeLife AssessmentUrologyVoiding Dysfunction +7

Hospitalizations for osteoporosis-related fractures: Economic costs and clinical outcomes

Derek Weycker, Xiaoyan Li, Rich Barron, +2

Bone Reports

Prevalence of antibiotic resistance in US hospitals

John Edelsberg, Derek Weycker, Rich Barron, +6

Diagnostic Microbiology and Infectious Disease

AntibioticsDrug ResistanceHospital EpidemiologyAntimicrobial TherapyInfection Control +5

Predicting imminent risk for fracture in patients aged 50 or older with osteoporosis using US claims data

Machaon Bonafede, Ni Shi, Rich Barron, +3

Archives of Osteoporosis

Risk and Consequences of Chemotherapy-Induced Febrile Neutropenia in Patients With Metastatic Solid Tumors

Derek Weycker, Xiaoyan Li, John Edelsberg, +4

Journal of Oncology Practice

Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice

Derek Weycker, Rich Barron, John Edelsberg, +2

Breast Cancer Research and Treatment

NursingBreast OncologyCancer EpidemiologyMedicineCancer Management +5

Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: A retrospective cohort study

Derek Weycker, Jennifer L. Malin, John Kim, +4

Clinical Therapeutics

Retrospective Cohort StudySurgical OncologyMedicineCancer ManagementFilgrastim Prophylaxis +6

Costs Associated with Febrile Neutropenia in the US

Shannon L. Michels, Rich Barron, Matthew W. Reynolds, +3

PharmacoEconomics

Health EconomicsClinical EpidemiologyFebrile NeutropeniaHealth Care CostCost Effectiveness +5